/
PARP Inhibitors and Cancer:    What Do You Need to Know? PARP Inhibitors and Cancer:    What Do You Need to Know?

PARP Inhibitors and Cancer: What Do You Need to Know? - PowerPoint Presentation

pasty-toler
pasty-toler . @pasty-toler
Follow
386 views
Uploaded On 2019-01-22

PARP Inhibitors and Cancer: What Do You Need to Know? - PPT Presentation

This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 747789

trial parp cont phase parp trial phase cont brocade inhibitor olaparib inhibitors abbreviations response talazoparib study agent single bicr

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "PARP Inhibitors and Cancer: What Do Y..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

PARP Inhibitors and Cancer: What Do You Need to Know?Slide2

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide3

Poly(ADP-ribose) PolymerasesSlide4

PARP Involvement in DNA RepairSlide5

Challenges to the ModelSlide6

Alternative Models of PARP

InhibitionSlide7

Alternative Models of PARP Inhibition (cont)Slide8

PARP InhibitorsSlide9

Differences Among PARP InhibitorsSlide10

Single Agent DevelopmentSlide11

"Study 42": Single Agent OlaparibSlide12

Talazoparib Phase 1Slide13

Talazoparib Phase 2 (ABRAZO) Slide14

OlympiAD Study DesignSlide15

Primary Endpoint: PFS by BICRSlide16

Objective Response by BICRSlide17

Adverse Events (Any Grade) in ≥15%

of Patients Slide18

BROCADE Trial DesignSlide19

BROCADE Trial: Tumor ResponseSlide20

BROCADE Trial: PFSSlide21

Phase 1 Trial of Olaparib and CisplatinSlide22

PARP Inhibitor With PI3K Inhibitor for BRCA1-

Related Breast CancerSlide23

OlympiA: Olaparib in High-Risk Germline

BRCA

MutationsSlide24

Possible Role of PARP Inhibitor Therapy in Other Settings Slide25

Mechanisms of ResistanceSlide26

Platinum Cross-Resistance?Slide27

Conclusions and SummarySlide28

AbbreviationsSlide29

Abbreviations (cont)Slide30

Abbreviations (cont)